Binding thermodynamics and kinetics guided optimization of potent Keap1-Nrf2 peptide inhibitors

被引:43
|
作者
Lu, Meng-Chen [1 ,2 ]
Chen, Zhi-Yun [1 ,2 ]
Wang, Ya-Lou [1 ,2 ]
Jiang, Yong-Lin [1 ,2 ]
Yuan, Zhen-Wei [1 ,2 ]
You, Qi-Dong [1 ,2 ]
Jiang, Zheng-Yu [1 ,2 ,3 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Jiang Su Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[3] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 210009, Jiangsu, Peoples R China
来源
RSC ADVANCES | 2015年 / 5卷 / 105期
基金
中国国家自然科学基金;
关键词
PROTEIN-PROTEIN INTERACTION; STRESS-RESPONSE; NRF2; DISCOVERY; PATHWAY; RECOGNITION; INTERFACE; MECHANISM; PROVIDES;
D O I
10.1039/c5ra16262a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Activation of Nrf2 by directly inhibiting the Keap1-Nrf2 Protein-Protein Interaction (PPI) has gained research interest with regard to developing novel agents for treating inflammatory related diseases. In this study, computational methods were used to guide the rational activity improvement of peptide Keap1-Nrf2 inhibitors and to explore the Keap1 binding cavity. Terminal hydrophobic residues and Tyr residue replacements were introduced into the novel peptides. The experimental values of these peptides further confirmed the potential binding sites explored by the MD simulation. Finally, the most promising, peptide 5 with an intracyclic conformation showed a K-d value of 2.8 nM when binding to Keap1 and an IC50 value of 9.4 nM in the Keap1-Nrf2 PPI fluorescence polarization assay. It proved that the active conformation locking strategy is quite useful in Keap1-Nrf2 PPI inhibitor design. It also provided a useful probe to investigate the Keap1-Nrf2 PPI system.
引用
收藏
页码:85983 / 85987
页数:5
相关论文
共 50 条
  • [41] Validation of the multiple sensor mechanism of the Keap1-Nrf2 system
    Takaya, Kai
    Suzuki, Takafumi
    Motohashi, Hozumi
    Onodera, Ko
    Satomi, Susumu
    Kensler, Thomas W.
    Yamamoto, Masayuki
    FREE RADICAL BIOLOGY AND MEDICINE, 2012, 53 (04) : 817 - 827
  • [42] Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity
    Yasuda, Daisuke
    Nakajima, Mao
    Yuasa, Akihiro
    Obata, Rika
    Takahashi, Kyoko
    Ohe, Tomoyuki
    Ichimura, Yoshinobu
    Komatsu, Masaaki
    Yamamoto, Masayuki
    Imamura, Riyo
    Kojima, Hirotatsu
    Okabe, Takayoshi
    Nagano, Tetsuo
    Mashino, Tadahiko
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (24) : 5956 - 5959
  • [43] Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor
    Otake, Kazuki
    Ubukata, Minoru
    Nagahashi, Noboru
    Ogawa, Naoki
    Hantani, Yoshiji
    Hantani, Rie
    Adachi, Tsuyoshi
    Nomura, Akihiro
    Yamaguchi, Keishi
    Maekawa, Mariko
    Mamada, Hideaki
    Motomura, Takahisa
    Sato, Motohide
    Harada, Kazuhito
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (05): : 658 - 665
  • [44] Structure-Guided Conformational Restriction Leading to High-Affinity, Selective, and Cell-Active Tetrahydroisoquinoline-Based Noncovalent Keap1-Nrf2 Inhibitors
    Qin, Yuting
    Poulsen, Cecilie
    Narayanan, Dilip
    Chan, Camilla B.
    Chen, Xiangrong
    Montes, Beatriz Ralsi
    Tran, Kim T.
    Mukminova, Elina
    Lin, Chunyu
    Gajhede, Michael
    Bullock, Alex N.
    Olagnier, David
    Bach, Anders
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (21) : 18828 - 18864
  • [45] Mathematical modeling reveals quantitative properties of KEAP1-NRF2 signaling
    Liu, Shengnan
    Pi, Jingbo
    Zhang, Qiang
    REDOX BIOLOGY, 2021, 47
  • [46] Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway
    Kidokoro, Kengo
    Kadoya, Hiroyuki
    Cherney, David Z. I.
    Kondo, Megumi
    Wada, Yoshihisa
    Umeno, Reina
    Kishi, Seiji
    Nagasu, Hajime
    Nagai, Kojiro
    Suzuki, Takafumi
    Sasaki, Tamaki
    Yamamoto, Masayuki
    Kanwar, Yashpal S.
    Kashihara, Naoki
    KIDNEY360, 2023, 4 (10): : 1454 - 1466
  • [47] Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury
    Zhang, Le
    Xu, Lijuan
    Chen, Haihu
    Zhang, Wannian
    Xing, Chengguo
    Qu, Zhuo
    Yu, Jianqiang
    Zhuang, Chunlin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 222
  • [48] Toward clinical application of the Keap1-Nrf2 pathway
    Suzuki, Takafumi
    Motohashi, Hozumi
    Yamamoto, Masayuki
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (06) : 340 - 346
  • [49] Molecular Basis of the KEAP1-NRF2 Signaling Pathway
    Suzuki, Takafumi
    Takahashi, Jun
    Yamamoto, Masayuki
    MOLECULES AND CELLS, 2023, 46 (03) : 133 - 141
  • [50] The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding
    Gacesa, Ranko
    Lawrence, Karl P.
    Georgakopoulos, Nikolaos D.
    Yabe, Kazuo
    Dunlap, Walter C.
    Barlow, David J.
    Wells, Geoffrey
    Young, Antony R.
    Long, Paul F.
    BIOCHIMIE, 2018, 154 : 35 - 44